News
12-08-2009, 04:41 AM
Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.
More... (http://www.news-medical.net/news/20091208/Pixantrone-demonstrates-substantial-reduction-in-cardiac-cell-toxicity-compared-to-anthracyclines.aspx)
More... (http://www.news-medical.net/news/20091208/Pixantrone-demonstrates-substantial-reduction-in-cardiac-cell-toxicity-compared-to-anthracyclines.aspx)